These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25903695)

  • 1. Isolation, Characterization of a Potential Degradation Product of Aspirin and an HPLC Method for Quantitative Estimation of Its Impurities.
    Acharya S; Daniel A; Gyadangi B; Ramsamy S
    J Chromatogr Sci; 2015 Oct; 53(9):1491-7. PubMed ID: 25903695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets.
    Galanopoulou O; Rozou S; Antoniadou-Vyza E
    J Pharm Biomed Anal; 2008 Sep; 48(1):70-7. PubMed ID: 18584991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability-indicating HPLC method for simultaneous quantification of 14 impurities in excedrin tablet formulations and identification of new impurity by LC-MS in accelerated stability studies.
    Dongala T; Katari NK; Palakurthi AK; Jonnalagadda SB
    Biomed Chromatogr; 2019 Oct; 33(10):e4608. PubMed ID: 31145484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous Determination of Aspirin, Dipyridamole and Two of Their Related Impurities in Capsules by Validated TLC-Densitometric and HPLC Methods.
    El-Ragehy NA; Hassan NY; Tantawy MA; Abdelkawy M
    J Chromatogr Sci; 2016 Aug; 54(7):1120-8. PubMed ID: 27406124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterisation of degradant impurities in dipyridamole formulation.
    Venkata Subbaiah B; Sree Ganesh KK; Vamsi Krishna G; Vyas K; Vasu Dev R; Subramanyam Reddy K
    J Pharm Biomed Anal; 2012 Mar; 61():256-64. PubMed ID: 22206889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
    Nageswara Rao R; Narasa Raju A; Narsimha R
    J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product.
    Luo Z; Deng Z; Liu Y; Wang G; Yang W; Hou C; Tang M; Yang R; Zhou H
    Talanta; 2015 Jul; 139():67-74. PubMed ID: 25882410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, Characterization, Synthesis and Quantification of Related Impurities of Liguzinediol.
    Cheng D; Zhou Y; Li W; Shan CX; Chai C; Cui XB; Kang B; Wang TL; Wen HM
    J Chromatogr Sci; 2015 Sep; 53(8):1280-8. PubMed ID: 25680683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexity in estimation of esomeprazole and its related impurities' stability in various stress conditions in low-dose aspirin and esomeprazole magnesium capsules.
    Reddy PS; Hotha KK; Sait S
    Sci Pharm; 2013; 81(2):475-92. PubMed ID: 23833714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation, structure characterization and quantification of related impurities in asperosaponin VI.
    Ji D; Liu YF; Wang QH; Zhang CF; Yang ZL
    Chin J Nat Med; 2013 Jul; 11(4):419-26. PubMed ID: 23845554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a stability-indicating RP-HPLC method for the simultaneous estimation of process related impurities and degradation products of rasagiline mesylate in pharmaceutical formulation.
    Reddy PS; Sudhakar Babu K; Kumar N
    J Chromatogr Sci; 2013 Mar; 51(3):242-9. PubMed ID: 22988002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, synthesis and quantification of process-related impurities in auraptene.
    Li YG; Chen HF; Tu MZ; Zhang PZ; Wang XY; Yuan JB; Yang WL
    J Pharm Biomed Anal; 2011 Sep; 56(2):191-9. PubMed ID: 21705169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
    Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
    J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of unknown degradation impurities in beclomethasone dipropionate cream formulation using HPLC, ESI-MS and NMR.
    Sambandan E; Kathavarayan T; Sellappan S; Shiea J; Ponnusamy VK
    J Pharm Biomed Anal; 2019 Apr; 167():123-131. PubMed ID: 30771645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR.
    Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
    J Pharm Biomed Anal; 2012 Apr; 63():62-73. PubMed ID: 22341479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of potential impurities by a stability indicating UV-HPLC method in niacinamide active pharmaceutical ingredient.
    Thomas S; Bharti A; Tharpa K; Agarwal A
    J Pharm Biomed Anal; 2012 Feb; 60():86-90. PubMed ID: 22115882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.